Documents | Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab: review decision - October 2013 information
Appendix A: decision paper presented to the Institute's Guidance Executive ^{PDF 105.75 KB} 21 October 2013
TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab: review proposal information
Appendix A: provisional matrix of stakeholders ^{PDF 104.84 KB} 27 August 2013
Appendix B: proposal paper presented to the Institute's Guidance Executive ^{PDF 366.23 KB} 27 August 2013
TA208 Gastric cancer (HER2-positive metatastic) - trastuzumab: press release information
Download PDF version ^{PDF 73.9 KB} 06 December 2013

Gastric cancer (HER2-positive metastatic) - trastuzumab: equality impact assessment

Gastric cancer (HER2-positive metastatic) - trastuzumab: equality impact assessment ^{PDF 75.03 KB} 24 November 2010

Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination

Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination information
Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination ^{PDF 301.37 KB} 29 September 2010
Gastric cancer (HER2-positive metastatic) - trastuzumab: response to consultee, commentator and public comments on the ACD and comments from website consultation ^{PDF 263.11 KB} 29 September 2010
Gastric cancer (HER2-positive metastatic) - trastuzumab: consultee and commentator comments on the ACD
Gastric cancer (HER2-positive metastatic) - trastuzumab: Cancer Research UK response ^{PDF 151.24 KB} 29 September 2010
Gastric cancer (HER2-positive metastatic) - trastuzumab: Centre for Reviews and Dissemination - ERG response ^{PDF 127.07 KB} 29 September 2010
Gastric cancer (HER2-positive metastatic) - trastuzumab: Roche response ^{PDF 643.29 KB} 29 September 2010
Gastric cancer (HER2-positive metastatic) - trastuzumab: Royal College of Nursing response ^{PDF 59.29 KB} 29 September 2010
Gastric cancer (HER2-positive metastatic) - trastuzumab: Royal College of Physicians/NCRI/RCR/ACP/JCCO response ^{PDF 75.91 KB} 29 September 2010
Gastric cancer (HER2-positive metastatic) - trastuzumab: Welsh Assembly Government response ^{PDF 135.26 KB} 29 September 2010
Gastric cancer (HER2-positive metastatic) - trastuzumab: public comments on the ACD
Gastric cancer (HER2-positive metastatic) - trastuzumab: comments received from the public through the NICE website ^{PDF 89.54 KB} 29 September 2010
Gastric cancer (HER2-positive metastatic) - trastuzumab: comments received from the public by letter ^{PDF 83.02 KB} 29 September 2010

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): appraisal consultation

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): appraisal consultation
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): appraisal consultation document information
Evaluation report
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): pre-meeting briefing ^{PDF 129.14 KB} 06 July 2010
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): evidence review group's report ^{PDF 625.1 KB} 06 July 2010
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): addendum to the Evidence Review group report ^{PDF 13.38 KB} 06 July 2010
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): ERG response to inaccuracies ^{PDF 24.51 KB} 06 July 2010
Non-manufacturer submissions
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): non-manufacturer submissions ^{PDF 52.72 KB} 06 July 2010
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): RCP non-manufacturer statement ^{PDF 31.48 KB} 06 July 2010
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): Roche Pharmaceuticals ^{PDF 1.8 MB} 06 July 2010
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): NICE clarification letter ^{PDF 37.85 KB} 06 July 2010
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): manufacturer response ^{PDF 812.97 KB} 06 July 2010

NICE consults on new treatment for metastatic gastric cancer

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the provisional matrix

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the provisional matrix ^{PDF 26.92 KB} 24 December 2009

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the draft scope

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the draft scope ^{PDF 21.56 KB} 24 December 2009

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): final scope

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): final scope ^{PDF 23.32 KB} 24 December 2009